Programme coordination and instruments to achieve the structural goals of the priority programme

DFG优先项目的设立是为了：建立一个网络，协调德国领先的肥大细胞实验室和中心的努力，通过从小鼠模型中的发现过渡到为患者提供更好的治疗方案，成功地领导德国的肥大细胞研究。􀂾它还将在国际上加强德国科学家在这一研究指导领域的地位􀂾，并简化实验室之间的相互作用，这些实验室可以确定肥大细胞激活的相关途径和疾病模型中的影响，以及各种专业的临床科学家，他们可以将这些发现转移到靶向这些途径的条件下，可以测试它们在预防或控制细菌和其他感染，过敏性和自身免疫性疾病等疾病中的安全性和有效性。此外，德国还通过研究毒液和其他毒素引起的疾病以及肿瘤􀂾，招募和培训优秀的年轻科学家，以确保德国科学在这一新兴研究领域的强大地位。该计划的一个特别重点是促进和便利目前在国外工作的该领域的德国领先科学家返回（人才回流）􀂾，发起和促进与国际肥大细胞网络的积极和持续的合作努力和富有成效的互动。（例如EMBRN，欧洲肥大细胞和嗜碱性粒细胞网络）和肥大细胞驱动疾病的联合体（例如欧盟成本行动BM 1007“肥大细胞和嗜碱性粒细胞”）􀂾启动并建立与生物技术公司和大型制药公司合作伙伴交流和互动的平台本申请介绍了优先计划内正在进行和预期进行的结构性工作和行动，并要求为其协调和实施提供更多资金。

This DFG priority programme was set up to: 􀂾 establish a network and coordinate the efforts of leading mast cell laboratories and centers in Germany 􀂾 successfully lead mast cell research in Germany through the transition from findings in mouse models to better treatment options for patients. It will also internationally strengthen the position of German scientists in this field of research 􀂾 guide and streamline the interactions between labs that can identify relevant pathways of mast cell activation and effects in models of disease and clinical scientists of various specialties who can transfer these findings to conditions in which targeting these pathways can be tested for their safety and efficacy in preventing or controlling diseases such as bacterial and other infections, allergic and autoimmune diseases, conditions caused by venoms and other toxins, and tumors 􀂾 provide for the recruitment and training of excellent junior scientists to secure a strong position of German science in this emerging field of research. A special focus of this programme is also to promote and facilitate the return of leading German scientists in this field who are presently working abroad (brain gain) 􀂾 launch and promote active and continued collaborative efforts and productive interactions with international mast cell networks (such as EMBRN, the European Mast Cell and Basophil Network) and consortia for mast cell-driven diseases (e.g. the EU COST ACTION BM1007 “Mast Cells and Basophils”) 􀂾 start and build up a platform for the exchange and interaction with biotechs and big pharma partners This application describes ongoing and anticipated structural efforts and actions within the priority programme and asks for further funding of their coordination and implementation.